Zolgensma: fatal cases of acute liver failure (Cell and Gene Therapy Catapult – Regulatory Round-up – January 2023)
Fiche du document
Auteur
Date
17 mai 2023
Discipline
Type de document
Périmètre
Identifiant
- handle: 10670/1.605fos
Source
Organisation
Sujets proches
Hepatic failure Failure of the liver Hepatic insufficiency Liver failure Therapy, GeneCiter ce document
adelage, « Zolgensma: fatal cases of acute liver failure (Cell and Gene Therapy Catapult – Regulatory Round-up – January 2023) », ELSIBI, ID : 10670/1.605fos
Métriques
Partage / Export
Résumé
Fatal cases of acute liver failure were recently reported in patients treated with Zolgensma (onasemnogene abeparvovec), a gene therapy medicine for the treatment of spinal muscular atrophy (SMA). A direct healthcare professional communication (DHPC) will be issued by the EMA in due course. Please find details here. See all of Catapult’s Regulatory Round-up for January 2023 here. Published on the 1st of February 2023.